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INTRODUCTION
Obstruction of the superior vena cava (SVC) is a recog-
nized complication of lung cancer. Before the mid twenti-
eth century, malignancy accounted for one-third of all cases
of SVC syndrome (SVCS). Most cases occurred secondary to
benign disease (1). Today, however, intrathoracic malignan-
cy has far surpassed benign disease as the primary cause of
SVC obstruction. Approximately 73 to 97% of SVCS cases
occur secondary to malignancy, and the most frequent cause
is lung malignancy. Approximately 3 to 5% of patients with
lung malignancy develop the syndrome (2). Obstruction of
the SVC occurs either via direct extension or compression
due to the primary tumor or via invasion of the mediastinal
lymph nodes. In addition, progressive tumor growth may
violate the vascular intima and serve as a nidus for throm-
bus formation, which can evolve to extensive thrombosis of
vessels.
SVC syndrome due to malignancy produces acute distress
and degrades the quality of life during the limited survival.
Therefore, the goal of SVCS therapy is rapid and effective
palliation of the symptoms, rather than long-term remis-
sion. Traditionally, most patients with SVCS secondary to
malignancy have been treated non-operatively, with radio-
therapy, chemotherapy, or both. With radiotherapy, dimin-
ished venous distension and subjective improvement usual-
ly do not occur until three to seven days after beginning thera-
py. Approximately 46 to 70% of patients with bronchogenic
carcinoma will demonstrate a symptomatic response to radio-
therapy or combined radiotherapy and chemotherapy with-
in the first two weeks (3, 4).
More recently, endovascular stents have been used success-
fully to alleviate symptoms. Prompt, persistent resolution of
symptoms is achieved in 75 to 95% of patients (5, 6). This
paper reviews our experience in treating SVCS to assess the
effectiveness of endovascular stenting for palliation of SVCS. 
MATERIALS AND METHODS
Between September 2001 and February 2003, percuta-
neous endovascular stent (Wall Stent, Boston Scientific, Nas-
tick, MA, U.S.A.) insertion was attempted in 10 patients (8
men, 2 women), age range 37-63 (mean 54) yr, with symp-
tomatic occlusion of the SVC. Wall stents varied in length
(4-10 cm) and diameter (10-14 mm). The most commonly
used was 8 cm×14 mm. All patients had known malig-
nant disease of thorax (squamous cell carcinoma: 4, adeno-
carcinoma: 3, poorly differentiated carcinoma: 3). Eight
patients had been treated previously with chemotherapy and
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Endovascular Stenting as a First Choice for the Palliation of Superior
Vena Cava Syndrome
To assess the effectiveness of endovascular stenting for the palliation of superior
vena cava (SVC) syndrome, endovascular stent insertion was attempted in 10
patients with symptomatic occlusion of the SVC. All the patients had known malig-
nant disease of the thorax. Eight patients had been treated previously with chemo-
therapy and radiotherapy (n=5), chemotherapy alone (n=2), or pneumonectomy
and radiotherapy (n=1). After developing SVC syndrome, all the patients were
stented before receiving any other treatment. After single or multiple endovascular
stents were inserted, five of eight patients were treated with chemotherapy and
radiotherapy (n=2) or chemotherapy alone (n=3). Resolution of symptoms was
achieved in nine patients within 72 hr (90%). In one patient, the symptoms did not
disappear until a second intervention. At follow up, symptoms had recurred in two
of ten patients (20%) after intervals of 15 and 60 days. Five patients have died
from their cancers, although they remained free of symptoms of SVC occlusion
until death. In conclusion, endovascular stent insertion is an effective treatment for
palliation of SVC syndrome. Endovascular stent insertion can be considered the
first choice of treatment, due to the immediate relief of symptoms and excellent
sustained symptomatic relief.
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radiotherapy (n=5), chemotherapy alone (n=2), or pneumonec-
tomy and radiotherapy (n=1).
After developing SVCS, all the patients were stented before
attempting any other palliative treatment. Digital subtrac-
tion angiography was performed before stenting to localize
the site of obstruction. The SVC was stenosed or occluded
in all cases by tumor and thrombotic occlusion of the SVC.
Venous access was achieved via the right jugular vein in four
patients, via the left jugular vein in one patient, and via the
right femoral vein in five patients. After navigating the ste-
nosed or occluded segment of the SVC with a angiographic
catheter and guidewire, one (n=7) or two (n=3) endovascu-
lar stents were inserted. Catheter-directed thrombolysis was
not used. Primary clinical patency was defined as the resolu-
tion of edema after the procedure; if another procedure was
needed to relieve SVCS, it was recorded as secondary clinical
patency.
After stenting, five patients were treated with either chemo-
radiation (n=2) or chemotherapy alone (n=3). Retrospective
analysis of the clinical records was used to assess the effec-
Fig. 1. (A) Venous Doppler of superior vena cava demonstrating near total obstruction (arrowheads) in the first stent (arrows), 2 weeks
after the first procedure. (B) Fluoroscopic images show sequence of procedure for placement and balloon dilatation of 6 cm×14 mm the
second stent through the first stent, across the lesion. (C) Radiography showing two stents placement, after the second procedure. Arrow
and arrowhead indicate the upper ends of the second and first stent respectively.
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tiveness of endovascular stenting for the palliation of SVCS.
RESULTS
Stent placement was successful in all patients. Symptom
resolution was achieved in nine patients within 72 hr (90%).
Initial clinical success was achieved in 90% (9/10). Primary
clinical patency was achieved in 77.8% (7/9). At follow up,
symptoms due to thrombosis recurred in two of nine patients
after 15 or 60 days; both were successfully resolved by repeat-
ed stenting (Fig. 1). Therefore, secondary clinical patency rate
was 100%. These two patients took part early in the trial,
when we did not use anticoagulation or antiplatelet therapy.
Subsequently, warfarin 5 mg and acetyl salicylic acid 300 mg
were used to prevent thrombosis.
Symptom-free survival ranged from 12 days to 14 months
(mean 6.7 months). Presently, five patients are alive, remain
asymptomatic, and have a patent stent. Five patients have
died from their cancers; however, they remained free of symp-
toms of SVC occlusion until death.
DISCUSSION
Superior vena cava syndrome generally occurs as a result
of either compression by an adjacent tumor or compression
by lymph nodes. A tumor invades the vena cava much less
frequently in advanced stages of disease (7). Patients with
SVCS from lung malignancy have a very poor prognosis. The
response to therapy in patients with lung malignancy and
SVCS may have an impact on survival. In one series, those
who did not respond to non-operative therapy within 30 days
had a significantly lower one-year survival (7%) than those
who responded to therapy (17 to 24%). Patients who received
no therapy or who developed changes in mentation and com-
promised airways had a median survival of only six weeks
(3, 8, 9).
Four types of treatment are available for patients with SVCS.
General medical treatment (i.e., bed rest, elevation of the
head, diuretics, steroids, and anticoagulation) is of limited
clinical benefit (2). Radiation therapy is widely advocated
for SVCS caused by radiosensitive tumors and provides relief
by reducing tumor volume (10). Radiotherapy and chemo-
therapy are the standard forms of treatment, and a combina-
tion of the two has been used (11). Symptom improvement
of 75-90% has been reported, although other studies have
obtained less promising results (46% success with radiation
therapy for non-small cell carcinoma and 62-80% with chemo-
therapy for small cell carcinoma) (11, 12).
Traditional therapies require 2-4 weeks to show an effect
(11, 13). Furthermore, SVCS recurs in 20-50% of cases and
only symptomatic treatment is possible. More aggressive radi-
ation therapy has achieved responses of up to 90%. Never-
theless, high-dose radiation therapy has many complications.
Since these affect the quality of life of a patient whose life ex-
pectancy is only 6 months, they may be considered unaccept-
able and counterproductive, as radiation therapy can induce
fibrotic changes that further constrict the vessels.
After Charnsangavej et al. (14) introduced endovascular
stenting in dogs to treat obstruction of the vena cava, the
development of endovascular stenting has continued. The
procedure is easy to perform and well tolerated by patients.
Complications are minimal and, in terms of symptom relief,
the results are encouraging. The Wall stent is the most com-
mon endovascular device used to treat SVCS, although the
Palmaz and Gianturco stents have also been used with suc-
cess.
We attempted percutaneous endovascular stent (Wall Stent,
Boston Scientific, Nastick, MA, U.S.A.) insertion in 10 patients.
The efficacy of stenting a central venous obstruction was clear.
Nicholson et al. (13) presented convincing data comparing
palliative radiation therapy and endovascular stenting. Symp-
tom improvement usually occurred within 48-72 hr of stent
placement and, 90% of patients remained symptom-free
until death, as compared with only 12% of those who were
treated with palliative radiation therapy. They concluded
that stent placement was a more effective palliative therapy
and recommended stenting as the procedure of choice.
In the Cochrane systematic review (15) of treatment for
malignant SVC obstruction, stent insertion provided relief
of symptoms more rapidly, and in a higher proportion of
patients (95%) than did radiation therapy or chemotherapy.
Others have reported success rates of 90 to 100% in patients
with malignancy-related SVCS treated with combined endo-
vascular therapy (thrombolysis, angioplasty, and stent place-
ment) (16). Kee et al. (6) reported technical success in 56 of
59 patients (95%), primary clinical patency was 79%, and
secondary clinical patency was 93% with mortality and mor-
bidity rates of 3 and 10%, respectively. In our patients, ini-
tial clinical success was achieved in 90% (9/10). Primary clini-
cal patency was achieved in 77.8% (7/9). At follow up, symp-
toms due to thrombosis recurred in two of nine patients after
15 or 60 days; both were successfully resolved by repeated
stenting. In our patients, secondary clinical patency was 100%.
Gross et al. (17) reported no recurrences in 13 patients,
with follow-ups ranging from 3 to 180 days. Rosch et al. (18)
had 1 recurrence in a group of 20 patients, with follow-ups
ranging from 1 to 11 months. The reported recurrence rate
ranges from 0 to 45%. In our patients, symptoms recurred
in two of nine patients (22.2%) after 15 and 60 days, both
were thrombotic occlusions and were relieved by placement
of another stent.
The most common complication of this therapy is stent
thrombosis, which has been successfully treated with throm-
bolysis or further stent insertion (19). Early (within one month
of stenting) thrombosis occurs in 8-20% and late (more than
one month after endovascular stenting) thrombosis occurs522 Y.-I. Kim, K.-S. Kim, Y.-C. Ko, et al.
in 5-45%. Thrombosis is significantly reduced when long-
term anticoagulation (warfarin, platelet inhibitors) is used
following endovascular stenting (17). After we experienced
one early and another late thrombosis, we began to use war-
farin and platelet inhibitors. Since no thrombosis occurred
during the long-term follow-up period, this treatment seems
adequate to prevent further thrombosis.
In summary, our results with endovascular stents in the
initial treatment of SVCS of malignant cause were excellent.
Percutaneous endovascular stent insertion is an effective treat-
ment for palliation of SVC syndrome. Endovascular stent
insertion  is the first choice of treatment as it produces imme-
diate relief of symptoms and excellent sustained symptomat-
ic relief. Furthermore, stent insertion does not interfere with
subsequent radiation or chemotherapy. The immediate and
late complications that can arise are preventable and easily
resolved.
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